IL275070A - FCRN antibodies and methods of using them - Google Patents
FCRN antibodies and methods of using themInfo
- Publication number
- IL275070A IL275070A IL275070A IL27507020A IL275070A IL 275070 A IL275070 A IL 275070A IL 275070 A IL275070 A IL 275070A IL 27507020 A IL27507020 A IL 27507020A IL 275070 A IL275070 A IL 275070A
- Authority
- IL
- Israel
- Prior art keywords
- methods
- fcrn antibodies
- fcrn
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598402P | 2017-12-13 | 2017-12-13 | |
| US201862701354P | 2018-07-20 | 2018-07-20 | |
| PCT/US2018/065568 WO2019118791A1 (en) | 2017-12-13 | 2018-12-13 | Fcrn antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL275070A true IL275070A (en) | 2020-07-30 |
Family
ID=65041911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL275070A IL275070A (en) | 2017-12-13 | 2020-06-02 | FCRN antibodies and methods of using them |
Country Status (11)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| JP7486437B2 (ja) | 2018-06-08 | 2024-05-17 | アルジェニクス ビーブイ | 免疫性血小板減少症を治療する組成物及び方法 |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| CA3148826A1 (en) * | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| ES2992247T3 (es) | 2020-01-08 | 2024-12-11 | argenx BV | Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo |
| CA3183153A1 (en) * | 2020-06-17 | 2021-12-23 | Christian HINDERER | Compositions and methods for treatment of gene therapy patients |
| CN116782939A (zh) * | 2020-11-06 | 2023-09-19 | 动量制药公司 | FcRn抗体及其使用方法 |
| CA3200972A1 (en) * | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
| MX2023012032A (es) * | 2021-04-12 | 2023-12-08 | Momenta Pharmaceuticals Inc | Composiciones y métodos para tratar la miastenia gravis pediátrica. |
| CN116234827B (zh) * | 2021-09-03 | 2026-07-14 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别FcRn的抗体及其应用 |
| CN114129730A (zh) * | 2021-09-16 | 2022-03-04 | 宁夏大学 | FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用 |
| MX2024007806A (es) * | 2022-01-17 | 2024-07-04 | argenx BV | Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos. |
| KR20250037789A (ko) | 2022-06-15 | 2025-03-18 | 아르젠엑스 비브이 | Fcrn/항원-결합 분자 및 사용 방법 |
| US20250034260A1 (en) | 2023-07-05 | 2025-01-30 | Sanofi | Fcrn antagonists for treatment of igg-related diseases and disorders |
| JP2026526949A (ja) | 2023-07-31 | 2026-08-10 | メディトックス インク． | 抗体及びそれを含む免疫疾患治療用薬学的組成物 |
| TW202527982A (zh) | 2023-09-11 | 2025-07-16 | 美商默門塔醫藥公司 | Fcrn抗體之醫藥組成物 |
| WO2025186787A1 (en) * | 2024-03-08 | 2025-09-12 | Momenta Pharmaceuticals, Inc. | Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| US7662928B2 (en) | 2003-08-08 | 2010-02-16 | The Research Foundation Of State University Of New York | Anti-FcRn antibodies for treatment of auto/allo immune conditions |
| CA2534973A1 (en) | 2003-08-08 | 2005-02-17 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatment of auto/allo immune conditions |
| CN101124245A (zh) | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| EP1865986B1 (en) | 2005-03-08 | 2016-02-17 | Pfizer Products Inc. | Anti-ctla-4 antibody compositions |
| CA2637929A1 (en) | 2006-01-25 | 2007-08-02 | The Research Foundation Of State University Of New York | Anti-fcrn antibodies for treatement of auto/allo immune conditions |
| WO2007104529A2 (en) | 2006-03-13 | 2007-09-20 | Ablynx N.V. | Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| US8273351B2 (en) | 2008-04-25 | 2012-09-25 | Dyax Corp. | Fc receptor binding proteins |
| CN102549016B (zh) | 2009-06-30 | 2015-05-06 | 研究发展基金会 | 免疫球蛋白fc多肽 |
| US9067997B2 (en) * | 2011-05-25 | 2015-06-30 | Innate Pharma Sa | Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders |
| BR112013030352B1 (pt) | 2011-06-02 | 2020-05-19 | Dyax Corp. | anticorpo anti-fcrn isolado, composição farmacêutica que compreende o dito anticorpo, ácido nucleico isolado, vetor, célula e uso terapêutico do dito anticorpo |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US20130323242A1 (en) | 2012-06-01 | 2013-12-05 | Ophthotech Corp. | Compositions comprising an anti-pdgf aptamer and a vegf antagonist |
| US9844594B2 (en) | 2012-12-18 | 2017-12-19 | Merck Sharp & Dohme Corp. | Liquid formulations for an anti-TNF α antibody |
| EP2991666B1 (en) | 2013-05-02 | 2020-03-25 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| KR101815265B1 (ko) | 2013-06-20 | 2018-01-04 | 한올바이오파마주식회사 | FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물 |
| EP4241852A3 (en) | 2014-04-30 | 2023-11-15 | Hanall Biopharma Co., Ltd. | Antibody binding to fcrn for treating autoimmune diseases |
| JP6853178B2 (ja) | 2015-01-30 | 2021-03-31 | モメンタ ファーマシューティカルズ インコーポレイテッド | ＦｃＲｎ抗体およびその使用方法 |
| CA3022547A1 (en) * | 2015-05-12 | 2016-11-17 | Syntimmune, Inc. | Humanized affinity matured anti-fcrn antibodies |
| BR112019001806A2 (pt) | 2016-07-29 | 2019-05-07 | Momenta Pharmaceuticals, Inc. | anticorpos para fcrn e métodos de uso dos mesmos |
| JP6913527B2 (ja) | 2017-06-22 | 2021-08-04 | 株式会社小松製作所 | 油圧ポンプおよびモータ |
| MA51032A (fr) | 2017-12-08 | 2021-03-17 | Argenx Bvba | Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée |
| BR112020011310A2 (pt) | 2017-12-13 | 2020-11-17 | Momenta Pharmaceuticals, Inc. | anticorpos contra fcrn e seus métodos de uso |
| EP3762027A4 (en) | 2018-02-13 | 2022-06-15 | The Brigham & Women's Hospital, Inc. | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES |
| EA202190264A1 (ru) | 2018-07-20 | 2021-05-20 | Момента Фармасьютикалз, Инк. | КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn |
| IL280280B2 (en) | 2018-07-20 | 2024-11-01 | Momenta Pharmaceuticals Inc | Compositions of fcrn antibodies and methods of use thereof |
| JP7518821B2 (ja) | 2018-10-16 | 2024-07-18 | ユーシービー バイオファルマ エスアールエル | 重症筋無力症の治療方法 |
| CA3148826A1 (en) | 2019-08-01 | 2021-02-04 | Janssen Biotech, Inc. | Fcrn antibodies and methods of use thereof |
| CA3200972A1 (en) | 2020-11-06 | 2022-05-12 | Momenta Pharmaceuticals, Inc. | Fcrn antibodies and methods of use thereof |
-
2018
- 2018-12-13 BR BR112020011310-7A patent/BR112020011310A2/pt unknown
- 2018-12-13 KR KR1020257042733A patent/KR20260008175A/ko active Pending
- 2018-12-13 JP JP2020532551A patent/JP7420720B2/ja active Active
- 2018-12-13 EP EP18836751.0A patent/EP3723802A1/en active Pending
- 2018-12-13 AU AU2018386193A patent/AU2018386193B2/en active Active
- 2018-12-13 SG SG11202005021PA patent/SG11202005021PA/en unknown
- 2018-12-13 US US16/771,147 patent/US11773168B2/en active Active
- 2018-12-13 CN CN201880089334.7A patent/CN111712259A/zh active Pending
- 2018-12-13 WO PCT/US2018/065568 patent/WO2019118791A1/en not_active Ceased
- 2018-12-13 KR KR1020207019955A patent/KR102904658B1/ko active Active
- 2018-12-13 CA CA3085751A patent/CA3085751A1/en active Pending
-
2020
- 2020-06-02 IL IL275070A patent/IL275070A/en unknown
-
2023
- 2023-08-18 US US18/452,346 patent/US20240158509A1/en not_active Abandoned
- 2023-10-13 JP JP2023177190A patent/JP7690538B2/ja active Active
-
2025
- 2025-05-29 JP JP2025089576A patent/JP7904366B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11773168B2 (en) | 2023-10-03 |
| AU2018386193A1 (en) | 2020-06-25 |
| BR112020011310A2 (pt) | 2020-11-17 |
| SG11202005021PA (en) | 2020-07-29 |
| JP7904366B2 (ja) | 2026-08-12 |
| KR102904658B1 (ko) | 2025-12-29 |
| AU2018386193A8 (en) | 2020-07-02 |
| US20240158509A1 (en) | 2024-05-16 |
| KR20260008175A (ko) | 2026-01-15 |
| US20220064290A1 (en) | 2022-03-03 |
| JP2021506786A (ja) | 2021-02-22 |
| EP3723802A1 (en) | 2020-10-21 |
| CN111712259A (zh) | 2020-09-25 |
| WO2019118791A1 (en) | 2019-06-20 |
| CA3085751A1 (en) | 2019-06-20 |
| AU2018386193B2 (en) | 2025-04-24 |
| NZ765250A (en) | 2026-02-27 |
| JP7420720B2 (ja) | 2024-01-23 |
| JP2024016042A (ja) | 2024-02-06 |
| JP7690538B2 (ja) | 2025-06-10 |
| JP2025143252A (ja) | 2025-10-01 |
| KR20200098604A (ko) | 2020-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202005021PA (en) | Fcrn antibodies and methods of use thereof | |
| ZA201906730B (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL278821A (en) | Anti-SIRPA antibodies and methods of using them | |
| IL276731A (en) | Antibodies against CD73 and methods of using them | |
| IL265800A (en) | Anti-lag-3 antibodies and methods of using them | |
| SMT202300243T1 (it) | Anticorpi anti-tigit e relativi metodi d'uso | |
| IL252837A0 (en) | fcrn antibodies and methods of using them | |
| SG11202000387YA (en) | B7-h4 antibodies and methods of use thereof | |
| PL3491025T3 (pl) | Przeciwciała anty-FcRn i sposoby ich stosowania | |
| IL279648A (en) | Anti-SIRP-in-cell 1 antibodies and methods of using them | |
| SG10201912879YA (en) | Anti-sirp-alpha antibodies and methods of use thereof | |
| SG10201912563XA (en) | Anti-tim-3 antibodies and methods of use thereof | |
| IL265957A (en) | Anti-c1s antibodies and methods of using them | |
| IL274221A (en) | Antibodies to ANTI-APOC3 and methods of use | |
| IL273538A (en) | Anti-TRKB Monoclonal Antibodies and Methods of Use | |
| IL268568A (en) | TRAILshort antibody and methods of use | |
| SG11202106100VA (en) | Anti-il-36 antibodies and methods of use thereof | |
| IL279227A (en) | Anti-SIGLEC-7 antibodies and methods of using them | |
| ZA202002144B (en) | Antibodies and methods of use | |
| HK40038054A (en) | Fcrn antibodies and methods of use thereof |